2 hrs ago | Oregon Politico
The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.
6 hrs ago | New Urban Legends
A friend went into a kids hair salon and was asking about shampoo. The beautician said that there was a recent show on 20/20 or etc.
The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... The wealth-building power of compound interest will never cease to amaze me.
Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.
The wound care market may not be the most exciting biotech niche on the surface, but the multi-billion dollar industry's need for innovation has created an opportunity for smaller companies operating in the space.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson and Johnson could be sourcing commercial quantities of poppies outside Tasmania in 2015.
Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.
EDANA, the Association Serving the Nonwovens and Related Industries, has announced its new board of governors for 2013-2015, the most international board ever the group says with representatives from across Europe, the Middle East, United States and Asia.
With interest rates near zero, investors have been desperately seeking yield. As a result, one of the hottest trades for investors over the last three to four years has been buying large companies that pay high dividends.
A small implantable device, an artificial pancreas would continuously monitor blood-sugar levels and release insulin as needed in patients with Type 1 diabetics.
In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was likely sustainable for at least the next 15 years.
When shopping in any store that carries national brands, it's virtually impossible to remember which ones you're not supposed to buy for which reasons.
Johnson & Johnson won U.S. approval to use its rheumatoid arthritis drug Simponi to treat patients suffering from a moderate to severe inflammatory bowel disease.